Physician profile
Nayankumar A Patel
NPI 1972796985
$10,800.82
in general payments reported to CMS, 2019-2025
33 companies · $2,155 in 2025
The $2,155 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $757 · 2021: $1,394 · 2022: $1,869 · 2023: $1,557 · 2024: $2,189 · 2025: $2,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,725 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,725.28 |
| Education | $175.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,017.44 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $1,946.58 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $718.20 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $716.04 | 2021-2025 | |
| Amgen INC. | $686.18 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $565.43 | 2020-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $504.90 | 2020-2025 | Vafseo, Auryxia |
| Alexion Pharmaceuticals, INC. | $414.85 | 2021-2024 | Ultomiris, Soliris |
| Travere Therapeutics, INC. | $400.89 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $310.75 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $304.96 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $268.93 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.45 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $215.09 | 2020-2024 | Injectafer |
| Ani Pharmaceuticals, INC. | $206.74 | 2022-2023 | Purified Cortrophin Gel |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $188.31 | 2019-2025 | |
| Novo Nordisk INC | $178.91 | 2024-2025 | Ozempic |
| Glaxosmithkline, LLC. | $142.47 | 2019-2022 | |
| Genzyme Corporation | $127.41 | 2019-2023 | |
| Horizon Therapeutics Plc | $114.15 | 2021-2022 | |
| Medtronic, INC. | $109.92 | 2025 | Symplicity G3 |
| Ardelyx, INC. | $81.70 | 2024-2025 | Ibsrela |
| Amicus Therapeutics, INC. | $77.68 | 2019-2021 | |
| Vantive US Healthcare LLC | $74.20 | 2025 | Renal - Pd |
| Lilly USA, LLC | $58.66 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $35.12 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $24.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.87 | 2023 | Gattex |
| Veloxis Pharmaceuticals, INC. | $16.18 | 2022 | |
| Genentech USA, INC. | $16.09 | 2019 | |
| Hikma Pharmaceuticals USA | $14.70 | 2024 | Ryaltris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.86 | 2020 | |
| Baxter Healthcare | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayankumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.